Clinical research of Ibudilast on treating the steroid resistant allergic rhinitis.
- Author:
Hong LUO
1
;
Zezhang TAO
;
Nengbing YAN
;
Jinjun LIANG
;
Pengju WANG
;
Jinyun WANG
Author Information
1. Department of Otorhinolaryngology, the Central Hospital of Xiangfan City, Xiangfan, 441021, China. lh07103999370@163.com
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Anti-Allergic Agents;
therapeutic use;
Female;
Histamine H1 Antagonists, Non-Sedating;
therapeutic use;
Humans;
Leukotriene Antagonists;
therapeutic use;
Loratadine;
therapeutic use;
Male;
Middle Aged;
Pyridines;
therapeutic use;
Rhinitis, Allergic, Perennial;
drug therapy;
Rhinitis, Allergic, Seasonal;
drug therapy;
Steroids;
pharmacology;
Young Adult
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2009;23(2):63-66
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To compare the efficacy and safety of histamine H1 receptor antagonist loratadine with Leukotriene receptor antagonist Ibudilast in steroid resistant allergic rhinitis in a randomized controlled clinical trial.
METHOD:Thirty-five cases were treated by Ibudilast, and 34 cases by loratadine. Score system was used to compare the therapeutic effect of these two drugs on clinical symptoms and signs.
RESULT:Ibudilast shows a better curative effect than loratadine in the improvement of the total scores on clinical symptom and signs(P<0.05). Scores of symptoms and signs in Ibudilast group after 3, 7, 14 days decreased significantly by means of square analysis of single factor (P<0.01). No complication was observed.
CONCLUSION:Ibudilast can effectively alleviate the clinical symptoms and signs of steroid resistant allergic rhinitis with confirmed efficacy and safety, thus is recommended in steroid resistant allergic rhinitis. Increased doses or prolonged treatment of steroid is inappropriate.
